Efficacy of IV Acetaminophen in Acute Post-Operative Pain Control in Laparoscopic Roux-en-Y Gastric Bypass Surgery (LRYGBP) Patients

Morbid Obesity Clinical Trial

— IV APAP  

Official title:

A Randomized, Double-Blind, Placebo-Controlled, Single Center Study of IV Acetaminophen for the Treatment of Post-Operative Pain After Laparoscopic Roux-en-Y Gastric Bypass Surgery (LRYGBP)

Clinical Trial Details — Status: Unknown status

Administrative data

• NCT number: NCT01460667
• Other study ID #: IV APAP LRYGBP Study
• Status: Unknown status
• Phase: N/A
• First received: October 19, 2011
• Last updated: October 26, 2011
• Start date: October 2011

Study information

• Verified date: October 2011
• Source: McLaren Regional Medical Center
• Contact: Christina Lee, B.Sc.
• Phone: 517-505-4640
• Email: leechr28[@]msu.edu
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Laparoscopic Roux-en-Y gastric bypass (LRYGBP) is a common type of surgery in which length of stay and morbidity is intimately associated with post-operative nausea and vomiting (PONV) and recovery of bowel function. Medications most commonly used to control for post-operative pain are opioid medications, whose well known adverse effects include PONV. Currently, no studied adequate alternative to opiates exists for mild-moderate pain relief without the aforementioned risks.

The primary goal for this study is to evaluate the the administration of pre- and post-operative IV acetaminophen to determine if there is in an overall decrease in the use of opioid analgesics by patient controlled analgesia (PCA) and subsequent decrease in subjective PONV leading to sooner return of bowel function, enabling progression to oral intake and decrease in post-operative length of stay.

Description:

Opioid use during the post-operative period is a highly effective means of treatment for acute pain, however not without its adverse effects including post-operative nausea, vomiting (PONV), constipation, urinary retention, sedation and respiratory depression. Such factors have been implied in the literature to contribute to prolonged post-operative length of stay, delayed return to diet, return of bowel function and increased incidence of ileus. Alternatively, non-opioids, such as acetaminophen, aspirin, NSAIDs, and selective cyclo-oxygenase-2 inhibitors, can be utilized for acute pain, either alone or in combination with opioids. In the bariatric post-surgical population, NSAIDS both oral and IV (Toradol, Ibuprofen) are not recommended due to their potential bleeding tendency, anti-inflammatory effect, and ulcerogenic effect.

The LRYGBP may be classified as a surgery type associated with mild to moderate post-operative pain. Therefore, the mode of pain relief could directly affect the length of stay. The advent of IV acetaminophen serves as a opportunity to investigate in detail the efficacy of this non-opioid medication in the management of acute pain in the immediate post-operative period without the aforementioned adverse effects as expected from traditional opiate medications. A comprehensive approach to this study includes a prospective, double-blinded, randomized controlled trial of subjects who will undergo LRYGBP and randomized to the study agent (IV acetaminophen) or placebo.

Recruitment information / eligibility

• Status: Unknown status
• Enrollment: 85
• Est. primary completion date: October 2012
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 65 Years

Eligibility

Inclusion Criteria:

• patients who are scheduled to undergo laparoscopic Roux-en-Y gastric bypass surgery (LRYGBP) under general anesthesia.

• age 18 to 65 years

• BMI >35

• ASA scores 1,2, or 3

• a negative pregnancy test for female subjects of childbearing age

• ability to read, understand and provide informed consent to the study procedures

• ability to read and understand the use of pain and nausea scales (VAS)

Exclusion Criteria:

• known hypersensitivity to acetaminophen or opioids

• use of opioid or schedule II medications prior to commencement of the study >7 days

• those with chronic pain conditions or significant medical disease requiring pain control

• abnormal liver function (aspartate aminotransferase/alanine aminotransferase/bilirubin > 3X upper limit of normal range, active hepatic disease, clinically significant liver disease, cirrhosis or hepatitis)

• known or suspected alcohol, drug or opiate abuse or dependence; or participation in other clinical study within 30 days of surgery.

Related Conditions & MeSH terms

• Morbid Obesity
• Obesity, Morbid
• Pain, Postoperative

Intervention

Drug:
• IV acetaminophen
IV acetaminophen 1000 mg (100 mL) every 6 hours over 30 hours
• IV normal saline
0.9% normal saline IV, every 6 hours over 30 hours.

Locations

Country	Name	City	State
United States	McLaren Regional Medical Center	Flint	Michigan

Sponsors (2)

Lead Sponsor	Collaborator
McLaren Regional Medical Center	Mallinckrodt

Country where clinical trial is conducted

United States, 

References & Publications (5)

Macario A, Royal MA. A literature review of randomized clinical trials of intravenous acetaminophen (paracetamol) for acute postoperative pain. Pain Pract. 2011 May-Jun;11(3):290-6. doi: 10.1111/j.1533-2500.2010.00426.x. Epub 2010 Nov 28. Review. — View Citation

Madan AK, Ternovits CA, Speck KE, Tichansky DS. Inpatient pain medication requirements after laparoscopic gastric bypass. Obes Surg. 2005 Jun-Jul;15(6):778-81. — View Citation

Nguyen NT, Ho HS, Palmer LS, Wolfe BM. A comparison study of laparoscopic versus open gastric bypass for morbid obesity. J Am Coll Surg. 2000 Aug;191(2):149-55; discussion 155-7. — View Citation

Walder B, Schafer M, Henzi I, Tramèr MR. Efficacy and safety of patient-controlled opioid analgesia for acute postoperative pain. A quantitative systematic review. Acta Anaesthesiol Scand. 2001 Aug;45(7):795-804. — View Citation

Wininger SJ, Miller H, Minkowitz HS, Royal MA, Ang RY, Breitmeyer JB, Singla NK. A randomized, double-blind, placebo-controlled, multicenter, repeat-dose study of two intravenous acetaminophen dosing regimens for the treatment of pain after abdominal lapa — View Citation

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	difference in post-operative opiate consumption (PCA)		hourly, 30 hours from first dose of study agent
Secondary	post-operative subjective pain intensity		every 2 hours, 30 hours from first dose of study agent
Secondary	post-operative nausea and vomiting (PONV)		every 2 hours, 30 hours from first dose of study agent
Secondary	time to first post-operative drug administration		up to 30 hours from first dose of study agent
Secondary	time to return to flatus		up to 30 hours from first dose of study agent
Secondary	acceptance of rescue medication		up to 30 hours from first dose of study agent
Secondary	time to first request for rescue medication		up to 30 hours from first dose of study agent
Secondary	readiness for discharge		up to 72 hours from the first dose of study agent